Centene vs Elevance Health
CNC and ELV side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNC and ELV compare
Elevance Health is the larger company, worth 2.7 times as much as Centene ($91.1B against $33.8B).
Centene grew revenue faster over the last twelve months (13.9% versus 6.3% for Elevance Health).
Elevance Health keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with −2.5% at Centene.
Elevance Health pays a dividend yielding 1.6%; Centene does not pay one.
Elevance Health scores higher on the StockData Score (15 against 6 for Centene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNC | ELV |
|---|---|---|
| Size and price | ||
| Market cap | $33.8B | $91.1B |
| Share price | $68.45 | $420.07 |
| Change, 1 year | 83.3% | 24.9% |
| Change, 5 years | −7.7% | −0.47% |
| Beta (5Y) | 0.50 | 0.44 |
| Employees | 61K | 97K |
| StockData Score | ||
| Total score | 6 | 15 (better) |
| Valuation score | 2 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 18.7× |
| P/S | 0.2× (better) | 0.5× |
| P/B | 1.5× (better) | 2.0× |
| EV/EBITDA | – | 12.4× |
| P/FCF | 3.8× (better) | 14.5× |
| PEG | – | 14.81 |
| FCF yield | 26.5% (better) | 6.9% |
| Fair value | – | $477.08 |
| Margin of safety | – | 11.9% |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | 6.3% |
| Revenue growth, 5Y average | 11.9% (better) | 10.3% |
| Net income growth (TTM) | −348% | −7.4% (better) |
| EPS growth (TTM) | −358% | −4.3% (better) |
| EPS growth, 5Y average | – | 7.0% |
| Profitability | ||
| Gross margin | 8.0% | 89.1% (better) |
| Operating margin | −2.8% | 2.7% (better) |
| Net margin | −2.5% | 2.5% (better) |
| FCF margin | 4.4% (better) | 3.1% |
| Return on equity | −20.4% | 11.2% (better) |
| Return on invested capital | −22.7% | 11.5% (better) |
| Financial health | ||
| Debt / equity | 0.71 | 0.69 (better) |
| Net debt / EBITDA | – | −0.70 |
| Interest coverage | −8.6× | 3.8× (better) |
| Current ratio | 1.15 | 1.52 (better) |
| Altman Z-score | 2.83 | 3.03 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.6% |
| Payout ratio | – | 30.3% |
| Buyback yield | −0.01% | 3.0% (better) |
| Shareholder yield | −0.01% | 4.6% (better) |
| Ownership | ||
| Held by institutions | 98.8% | 94.0% |
| Held by insiders | 0.79% | 0.19% |
| Insider net buying, 12 months | −$14.6M | $493K (better) |
| Superinvestors holding | 3 | 8 (better) |
| Short interest, % of float | 2.1% | 2.2% |
Go deeper
- CNC stock overview
- CNC income statement
- CNC valuation and score
- ELV stock overview
- ELV income statement
- ELV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.